[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100539460":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":24,"locations":33,"responsibleParty":47,"collaborators":50,"id":62,"slug":63,"hasResults":64,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":68,"eligibilityCriteria":69,"healthyVolunteers":64,"sex":70,"minAge":71,"maxAge":18,"enrollmentInfo":72,"targetDuration":18,"studyType":75,"phases":76,"briefSummary":78,"conditions":79,"keywords":18,"overallStatus":81,"whyStopped":18,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":91},{"fullName":5,"class":6},"Central Hospital, Nancy, France","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Blood ponction","EXPERIMENTAL","All patients are in the experimental group",[13],"Diagnostic Test: Blood ponction",[15],{"type":16,"name":9,"description":9,"armGroupLabels":17,"otherNames":18},"DIAGNOSTIC_TEST",[9],null,[20],{"name":21,"affiliation":22,"role":23},"Catherine Malaplate, PhD, PharmD","CHRU Nancy","PRINCIPAL_INVESTIGATOR",[25,30],{"name":26,"role":27,"phone":28,"phoneExt":18,"email":29},"catherine Malaplate, PhD,PharmD","CONTACT","+33383855511","c.malaplate@chru-nancy.fr",{"name":31,"role":27,"phone":18,"phoneExt":18,"email":32},"Thérèse Jonveaux, PhD, MD","t.jonveaux@chru-nancy.fr",[34],{"facility":35,"status":18,"city":36,"state":37,"zip":38,"country":39,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":18},"CHRU De Nancy","Nancy","Grand Est","54500","France","FR",{"type":42,"coordinates":43},"Point",[44,45],6.18496,48.68439,{"lat":45,"lon":44},{"type":23,"investigatorFullName":48,"investigatorTitle":49,"investigatorAffiliation":5,"oldNameTitle":18,"oldOrganization":18},"Catherine MALAPLATE","Dr",[51,54,56,58,60],{"name":52,"class":53},"Thérèse Jonveaux","UNKNOWN",{"name":55,"class":53},"Laure Joly",{"name":57,"class":53},"Lucie Hopes",{"name":59,"class":53},"Maia Simon",{"name":61,"class":53},"Franck Schreiner","100539460","diagnostic-performance-of-plasma-biomarkers-of-alzheimers-disease-compared-with-csf-markers-100539460",false,"NCT06304129","Diagnostic Performance of Plasma Biomarkers of Alzheimer's Disease Compared With CSF Markers","Threshold Values and Diagnostic Performance of Plasma Biomarkers of Alzheimer's Disease Compared With CSF Markers","PLASM-ALZ","Inclusion Criteria:\n\n* Man or woman aged 18 or over\n* Person affiliated to a social security scheme or beneficiary of such a scheme\n* Person who has received full information on the organization of the research and has signed an informed consent form\n* Person whose care requires a lumbar puncture to measure markers of Alzheimer's disease\n\nExclusion Criteria:\n\n* Adult subject to a legal protection measure (guardianship, curatorship, safeguard of justice)\n* An adult unable to give consent\n* Persons deprived of their liberty by judicial or administrative decision\n* Persons under psychiatric care under articles L. 3212-1 and L. 3213-1.\n* Pregnant, parturient or breast-feeding women\n* Persons staying in a health or social establishment for purposes other than research.","ALL","18 Years",{"count":73,"type":74},189,"ESTIMATED","INTERVENTIONAL",[77],"NA",".The goal of this interventional study is to estimate the diagnostic performance of plasma biomarkers of interest (Aβ40 and Aβ42, P-Tau and NFL), enabling discrimination between patients with and without a pathophysiological AD process. The main questions it aims to answer are:\n\n* to define a threshold value for each of the plasma,\n* to describe the correlations between the plasma biomarkers of interest and the other biological analyses performed as part of care, in particular triglyceridemia, cholesterolemia, glycemia and proteinemia,\n* to describe biomarker results in relation to comorbidities, in particular dyslipidemia and diabetes\n* to describe the final diagnosis and results obtained for plasma biomarkers, for patients with intermediate results according to the A\u002FT\u002FN classification (A-\u002FT+ or A+\u002FT-) Participants will be selected among patients undergoing lumbar puncture for the differential diagnosis of AD at Nancy University Hospital.",[80],"Alzheimer Blood Biomarkers","NOT_YET_RECRUITING","2024-03-05",{"date":84,"type":85},"2024-03-12","ACTUAL",{"date":87,"type":74},"2024-04-02",{"date":89,"type":74},"2026-09-02",{"name":5,"class":6},1]